Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

此次收购将扩大临床实验室服务的覆盖范围，包括为全国患者和医疗机构提供广泛的 specialty testing 项目。

BURLINGTON, N.C. and MIAMI, Fla.

北卡罗来纳州伯灵顿和佛罗里达州迈阿密

,

，

Oct. 15, 2026

2026年10月15日

/PRNewswire/ --

/美通社/ --

Labcorp

Labcorp

(NYSE:

（纽约证券交易所：

LH

LH

), a global leader of innovative and comprehensive laboratory services, and

），作为创新且全面的实验室服务领域的全球领导者，以及

OPKO Health, Inc.

OPKO健康公司

(Nasdaq:

（纳斯达克：

OPK

OPK

), a multinational biopharmaceutical company, announced today that they have entered into an agreement for Labcorp to acquire select assets of

），一家跨国生物制药公司，今日宣布已达成协议，由Labcorp收购其部分精选资产。

BioReference Health

BioReference Health

, LLC, a wholly owned subsidiary of OPKO Health.

有限责任公司，OPKO Health 的全资子公司。

Continue Reading

继续阅读

OPKO

欧普科

Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 additional patient service centers. As part of the agreement, Labcorp will also acquire BioReference Health's proprietary 4Kscore.

通过此次交易，Labcorp将收购BioReference Health专注于临床和女性健康检测服务、泌尿科、矫正机构以及某些运营资产的实验室检测业务，包括80多个额外的患者服务中心。作为协议的一部分，Labcorp还将收购BioReference Health的专有产品4Kscore。

®

®

Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision, making this important test more broadly available to patients across the country.

Test 是一项经美国食品药品监督管理局（FDA）批准的血液检测，有助于在决定是否进行活检前预测发现侵袭性前列腺癌的可能性，从而使这项重要的检测在全国范围内更广泛地惠及患者。

When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, including a broad specialty testing menu, convenient patient service center network and robust data analytics and digital tools.

交易完成后，预计将为患者、医生和客户带来更便捷的途径，以获取 Labcorp 全面且高质量的实验室服务，包括广泛的专业检测项目、便捷的患者服务中心网络以及强大的数据分析和数字化工具。

'This acquisition strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country,' said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. 'By expanding our clinical, women's health, urology and corrections testing capabilities and broadening access to innovative diagnostics such as the FDA-approved 4Kscore Test, we can help providers make more informed decisions, improve patient care and increase access to the comprehensive laboratory services people need to live healthier lives.'.

“此次收购增强了我们向全国更多患者和医疗服务提供者提供负担得起、高质量、专业化诊断服务的能力，”Labcorp执行副总裁兼诊断部门总裁Bryan Vaughn表示。“通过扩展我们在临床、女性健康、泌尿学和矫正医学检测方面的能力，并扩大对包括FDA批准的4Kscore测试在内的创新诊断服务的可及性，我们能够帮助医疗服务提供者做出更明智的决策，改善患者护理，并增加人们获得全面实验室服务的机会，从而帮助他们过上更健康的生活。”

'This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business,' said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. 'Labcorp's national scale and capabilities will broaden patient and provider access to BioReference's 4Kscore Test to many more patients across the country.

“此次交易将使OPKO精简运营，并将我们的资源集中于我们的生物制药业务。”OPKO董事长兼首席执行官Phillip Frost医学博士表示。“Labcorp的全国规模和能力将扩大患者和医疗服务提供者对BioReference的4Kscore检测的获取范围，使全国更多患者受益。”

We believe this transaction is an important catalyst to further unlock additional value for our shareholders.'.

我们相信，此次交易是推动进一步为股东释放额外价值的重要催化剂。

The purchase price for the transaction is $722 million in cash at closing, subject to an upward or downward adjustment (if any) based on closing business revenues, and up to an additional $150 million in an earnout based on revenue from the 4Kscore Test. Labcorp expects the business revenue to be approximately $250 million in the first year after close, based on Labcorp's current post-closing forecasts..

本次交易的购买价格为在交割时支付7.22亿美元现金，并根据交割时的业务收入进行向上或向下调整（如有），此外还可能基于4Kscore检测的收入获得最高1.5亿美元的或有对价。根据Labcorp当前的交割后预测，Labcorp预计该业务在交割后的第一年收入约为2.5亿美元。

This transaction is subject to regulatory approvals and customary closing conditions. Until the transaction closes, there will be no changes to operations or services, and both companies will continue to operate independently.

本次交易须获得监管批准并满足惯例交割条件。在交易完成之前，运营和服务不会发生任何变化，两家公司将继续独立运营。

Lazard is serving as Labcorp's financial advisor, Hogan Lovells Cadwalader US LLP is serving as lead transaction counsel and Parker Poe is serving as real estate counsel.

拉扎德担任Labcorp的财务顾问，霍根·洛弗尔斯·卡德瓦拉德美国律师事务所担任首席交易法律顾问，帕克·波伊律师事务所担任房地产法律顾问。

Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, and Greenberg Traurig P.A. is serving as legal counsel.

派珀·桑德勒公司（Piper Sandler & Co.）担任OPKO的独家财务顾问，格林伯格·特劳里格律师事务所（Greenberg Traurig P.A.）担任法律顾问。

About Labcorp

关于Labcorp

Labcorp (NYSE:

Labcorp（纽约证券交易所：

LH

左心室

) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities.

）是全球领先的创新且全面的实验室服务提供商，帮助医生、医院、制药公司、研究人员和患者做出清晰而自信的决策。我们通过无与伦比的诊断和药物研发实验室能力，提供洞察并推动科学进步，以改善健康、提升生活质量。

The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at .

该公司近71,000名员工为约100个国家的客户提供服务，为美国食品药品监督管理局（FDA）在2025年批准的超过85%的新药和治疗产品提供了支持，并为全球患者进行了超过7.5亿次检测。了解更多详情，请访问。

www.labcorp.com

www.labcorp.com

.

。

About OPKO

关于 OPKO

OPKO Health, Inc. (Nasdaq:

OPKO Health, Inc.（纳斯达克：

OPK

OPK

) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit

）是一家跨国生物制药和诊断公司，旨在通过利用其在发现、开发和商业化方面的专业知识以及新颖的专有技术，在规模庞大且快速增长的市场中确立行业领先地位。欲了解更多信息，请访问

www.opko.com

www.opko.com

.

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This press release contains forward-looking statements, including, but not limited to, statements with respect to (a) the anticipated impact of the transaction including expanding access to comprehensive, high-quality laboratory services, (b) increased access to testing services and expanded testing capabilities including with respect to the 4Kscore Test, (c) anticipated timing to closing, final purchase price, post-closing revenue, and earnout for the 4Kscore Test, (d) other anticipated potential benefits of the acquisition to Labcorp and OPKO Health, and (e) required regulatory approvals and customary closing conditions..

本新闻稿包含前瞻性陈述，包括但不限于以下方面的陈述：(a) 交易的预期影响，包括扩大对全面、高质量实验室服务的获取；(b) 增加检测服务的可及性并扩展检测能力，包括涉及4Kscore检测的部分；(c) 预期的交割时间、最终购买价格、交割后收入以及4Kscore检测的盈利支付安排；(d) 此次收购对Labcorp和OPKO Health的其他预期潜在益处；以及(e) 所需的监管批准和惯例交割条件。

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the control of Labcorp or OPKO Health. These factors, in some cases, have affected and in the future (together with other factors) could affect the ability of Labcorp or OKPO Health to implement its respective business strategy, and actual results could differ materially from those suggested by these forward-looking statements.

每项前瞻性陈述均可能因各种重要因素而发生变化，其中许多因素超出 Labcorp 或 OPKO Health 的控制范围。在某些情况下，这些因素已经影响，并且未来（与其他因素一起）可能影响 Labcorp 或 OPKO Health 实施其各自业务战略的能力，实际结果可能与这些前瞻性陈述所暗示的结果存在重大差异。

As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements..

因此，提醒读者不要过度依赖任何前瞻性陈述。

Neither Labcorp nor OPKO Health has any obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in each of Labcorp's and OPKO Health's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the headings RISK FACTORS and MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, and in each of Labcorp's and OPKO Health's other filings with the SEC..

即使预期发生变化，Labcorp 和 OPKO Health 均无义务对这些前瞻性陈述进行任何更新。所有前瞻性陈述均受本警示性声明的全面限定。有关可能影响经营和财务结果的潜在因素、风险和不确定性的更多信息，包含在 Labcorp 和 OPKO Health 各自的最新 Form 10-K 年度报告及随后的 Form 10-Q 季度报告中，包括在各报告中的“风险因素”和“管理层对财务状况和经营成果的讨论与分析”标题下，以及 Labcorp 和 OPKO Health 向美国证券交易委员会（SEC）提交的其他文件中。

SOURCE Labcorp Holdings Inc

来源：Labcorp Holdings Inc

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示